Premium
Daclizumab: another option for highly active relapsing‐remitting MS
Author(s) -
Gaber Tarek,
Shippen Clare
Publication year - 2017
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.478
Subject(s) - daclizumab , relapsing remitting , multiple sclerosis , medicine , surgery , psychiatry , transplantation , tacrolimus
Daclizumab provides clinicians with a new treatment option for patients with relapsing‐remitting multiple sclerosis. Here the authors consider its benefits compared with other multiple sclerosis drugs and its likely place in therapy.